4SC AG - VSC

4SC AG, a clinical-stage biopharmaceutical company, engages in developing small-molecule drugs that target key indications in cancer with high unmet medical needs. The company’s drugs are intended to provide patients with various treatment options. Its pipeline is protected by a portfolio of patents and comprises three principal drug candidates that are in various stages of development. The company’s products in clinical development stage include Resminostat, an orally administered histone deacetylase inhibitor that is in Phase II clinical trial for the treatment of cutaneous T-cell lymphoma; and 4SC-202, an orally administered small molecule, which is in Phase Ib/II clinical trial for the treatment of cancer. Its products in preclinical stage include 4SC-208, a small molecule targeting two kinases crucial for Hedgehog/GLI signaling. The company also out-licenses its products to pharma and biotech companies for the treatment of cancer. 4SC AG has partnerships and collaborations with Yakult Honsha Co., Ltd.; Panoptes Pharma Ges.m.b.H; Maruho Co., Ltd.; Guangzhou LingSheng Pharma Tech Co. Ltd; Immunic AG; and BioNTech AG for development of its products. The company was founded in 1997 and is headquartered in Planegg, Germany.